JP2023539371A5 - - Google Patents
Info
- Publication number
- JP2023539371A5 JP2023539371A5 JP2023514424A JP2023514424A JP2023539371A5 JP 2023539371 A5 JP2023539371 A5 JP 2023539371A5 JP 2023514424 A JP2023514424 A JP 2023514424A JP 2023514424 A JP2023514424 A JP 2023514424A JP 2023539371 A5 JP2023539371 A5 JP 2023539371A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- inhibitors
- prostate cancer
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073502P | 2020-09-02 | 2020-09-02 | |
| US63/073,502 | 2020-09-02 | ||
| PCT/US2021/048607 WO2022051330A1 (en) | 2020-09-02 | 2021-09-01 | Abiraterone prodrugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539371A JP2023539371A (ja) | 2023-09-13 |
| JP2023539371A5 true JP2023539371A5 (enExample) | 2024-09-05 |
| JP7850366B2 JP7850366B2 (ja) | 2026-04-23 |
Family
ID=77951832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514424A Active JP7850366B2 (ja) | 2020-09-02 | 2021-09-01 | アビラテロンプロドラッグ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240050447A1 (enExample) |
| EP (1) | EP4208171A1 (enExample) |
| JP (1) | JP7850366B2 (enExample) |
| CN (1) | CN116490165A (enExample) |
| AU (1) | AU2021338271A1 (enExample) |
| CA (1) | CA3189989A1 (enExample) |
| IL (1) | IL300837A (enExample) |
| MX (1) | MX2023002478A (enExample) |
| WO (1) | WO2022051330A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7644713B2 (ja) | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| CA3207282A1 (en) * | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| WO2024107928A1 (en) | 2022-11-16 | 2024-05-23 | Propella Therapeutics, Inc. | Abiraterone decanoate composition and use in therapy |
| CN116287275B (zh) * | 2023-04-10 | 2024-04-05 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用 |
| WO2025240673A1 (en) * | 2024-05-15 | 2025-11-20 | Cardiff Oncology, Inc. | Cancer treatment using akt inhibitors and plk1 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20121788A1 (it) * | 2012-10-22 | 2014-04-23 | Olon Spa | Procedimento per la purificazione di abiraterone acetato |
| US20150337003A1 (en) * | 2013-01-18 | 2015-11-26 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
| CN104017045B (zh) * | 2014-06-23 | 2016-01-13 | 广州艾格生物科技有限公司 | 甾体cyp17抑制剂的新型药物前体及其应用、制备方法 |
| US10722527B2 (en) * | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
| CA3008909C (en) * | 2015-12-23 | 2023-10-03 | The University Of British Columbia | Lipid-linked prodrugs |
| CN106977577A (zh) * | 2017-04-21 | 2017-07-25 | 湖南师范大学 | 两类阿比特龙衍生物的合成 |
| CN118684633A (zh) | 2018-10-18 | 2024-09-24 | 埃萨制药股份有限公司 | 雄激素受体调节剂及其使用方法 |
| JP7644713B2 (ja) * | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| CA3207282A1 (en) * | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| CN118215466A (zh) * | 2021-09-08 | 2024-06-18 | 普洛佩拉治疗公司 | 口服阿比特龙制剂 |
| KR20240167653A (ko) * | 2022-03-01 | 2024-11-27 | 프로펠라 쎄라퓨틱스, 인크. | 아비라테론 데카노에이트 프로드러그 및 요법에서의 용도 |
-
2021
- 2021-09-01 JP JP2023514424A patent/JP7850366B2/ja active Active
- 2021-09-01 WO PCT/US2021/048607 patent/WO2022051330A1/en not_active Ceased
- 2021-09-01 US US17/635,106 patent/US20240050447A1/en active Pending
- 2021-09-01 CN CN202180070124.5A patent/CN116490165A/zh active Pending
- 2021-09-01 CA CA3189989A patent/CA3189989A1/en active Pending
- 2021-09-01 AU AU2021338271A patent/AU2021338271A1/en active Pending
- 2021-09-01 MX MX2023002478A patent/MX2023002478A/es unknown
- 2021-09-01 IL IL300837A patent/IL300837A/en unknown
- 2021-09-01 EP EP21778634.2A patent/EP4208171A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3797770B1 (en) | Softgel capsule comprising apalutamide | |
| JP2024533332A5 (enExample) | ||
| JP7141408B2 (ja) | 前立腺癌の併用療法 | |
| US20260041695A1 (en) | Combination therapies for treatment of breast cancer | |
| US20190343821A1 (en) | Intratumoral administration of sirolimus for treatment of prostate cancer | |
| CN116490165A (zh) | 阿比特龙前药 | |
| Miller et al. | Combination treatment options for castration-resistant prostate cancer | |
| US20250345342A1 (en) | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| JP6116481B2 (ja) | 神経内分泌腫瘍を治療する方法 | |
| EP4294395B1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 | |
| KR20220008870A (ko) | 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물 | |
| WO2024107928A1 (en) | Abiraterone decanoate composition and use in therapy | |
| JP2025508944A5 (enExample) | ||
| RU2024129008A (ru) | Пролекарства абиратерона деканоата и их применение в терапии | |
| Nwachukwu et al. | Advances in medical management of prostate cancer: a review | |
| HK40021384A (en) | Anti-androgens in combination with abiraterone acetate and prednisone for treating prostate cancer | |
| HK40046839A (en) | Androgen receptor modulator and uses thereof | |
| HK40015422A (en) | Intratumoral administration of sirolimus for treatment of prostate cancer | |
| HK40015422B (en) | Intratumoral administration of sirolimus for treatment of prostate cancer | |
| EA044267B1 (ru) | Фармацевтическая композиция, содержащая модулятор андрогенного рецептора |